OTCMKTS:BSTGBiostage Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biostage Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.55 -0.35 (-8.97 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$3.50Now: $3.55▼$4.1050-Day Range$2.45MA: $3.51▼$4.8052-Week Range$0.75Now: $3.55▼$4.88Volume1,075 shsAverage Volume4,896 shsMarket Capitalization$30.25 millionP/E RatioN/ADividend YieldN/ABeta0.34 ProfileAdvanced ChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Biostage. Previous Next 2.8 Community Rank Outperform VotesBiostage has received 49 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiostage has received 39 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiostage has received 55.68% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote “Outperform” if you believe BSTG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BSTG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiostage does not currently pay a dividend.Dividend GrowthBiostage does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biostage insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Biostage is held by insiders.Percentage Held by InstitutionsOnly 0.37% of the stock of Biostage is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Biostage is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biostage is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiostage has a P/B Ratio of 27.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BSTG Previous Symbol CUSIPN/A CIK1563665 Webhttp://www.biostage.com/ Phone774-233-7300Debt Debt-to-Equity Ratio0.08 Current Ratio1.73 Quick Ratio1.73Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book27.31Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,330,000.00 Net MarginsN/A Return on Equity-633.61% Return on Assets-369.33%Miscellaneous Employees15 Outstanding Shares8,520,000Market Cap$30.25 million Next Earnings Date5/12/2020 (Estimated) OptionableNot Optionable Receive BSTG News and Ratings via Email Sign-up to receive the latest news and ratings for BSTG and its competitors with MarketBeat's FREE daily newsletter. OTC:BSTG Rates by TradingView Biostage (OTCMKTS:BSTG) Frequently Asked Questions How has Biostage's stock been impacted by COVID-19 (Coronavirus)? Biostage's stock was trading at $3.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BSTG stock has increased by 1.4% and is now trading at $3.55. View which stocks have been most impacted by Coronavirus. When is Biostage's next earnings date? Biostage is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Biostage. How were Biostage's earnings last quarter? Biostage Inc (OTCMKTS:BSTG) released its quarterly earnings results on Friday, March, 27th. The company reported ($0.21) EPS for the quarter. View Biostage's earnings history. Has Biostage been receiving favorable news coverage? Media headlines about BSTG stock have trended very negative this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biostage earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutBiostage. Who are some of Biostage's key competitors? Some companies that are related to Biostage include Venus Concept (VERO), Apyx Medical (APYX), RenovaCare (RCAR), BeyondAirInc . (XAIR), TELA Bio (TELA), AIT Therapeutics (AITB), BRAINSWAY LTD/S (BWAY), Spectral Medical (EDTXF), PAVmed (PAVM), Pro-Dex (PDEX), SANUWAVE Health (SNWV), Nephros (NEPH), Nephros (NEPHD), Apollo Endosurgery (APEN) and Delcath Systems (DCTH). What other stocks do shareholders of Biostage own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biostage investors own include Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Portola Pharmaceuticals (PTLA), Biostage (BSTGD), Apellis Pharmaceuticals (APLS), Ardelyx (ARDX), ArQule (ARQL), Athersys (ATHX), Boxlight (BOXL) and Catalyst Biosciences (CBIO). Who are Biostage's key executives? Biostage's management team includes the following people: Mr. James J. McGorry, CEO & Director (Age 63)Mr. Thomas W. McNaughton, CFO & Sec. (Age 59)Yu Hong, Pres (Age 46)Ms. Ginger A. Abraham-Freel, Director of Quality & OperationsDr. William L. Fodor Ph.D., Chief Scientific Officer (Age 60) What is Biostage's stock symbol? Biostage trades on the OTCMKTS under the ticker symbol "BSTG." How do I buy shares of Biostage? Shares of BSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Biostage's stock price today? One share of BSTG stock can currently be purchased for approximately $3.55. How big of a company is Biostage? Biostage has a market capitalization of $30.25 million. Biostage employs 15 workers across the globe. View additional information about Biostage. What is Biostage's official website? The official website for Biostage is http://www.biostage.com/. How can I contact Biostage? Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The company can be reached via phone at 774-233-7300 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: Oversold
